Imagine a world where tuberculosis (TB) treatment could be drastically shortened, offering hope to millions suffering from this ancient disease. That’s exactly what’s on the horizon with sorfequiline, a groundbreaking drug that’s turning heads in the medical community. But here’s where it gets even more exciting: recent Phase 2 clinical trial data suggest that sorfequiline, when combined with pretomanid and linezolid (SPaL), could revolutionize TB therapy by enhancing both efficacy and safety for drug-sensitive TB patients.
In a bold move, the NC-009 trial, a multicenter Phase 2 study spanning 22 sites across South Africa, the Philippines, Georgia, Tanzania, and Uganda, put sorfequiline to the test alongside pretomanid and linezolid. The results? The 100 mg SPaL regimen outperformed the current standard HRZE therapy (isoniazid, rifampin, pyrazinamide, ethambutol) in fighting TB, all while maintaining a comparable safety profile. What’s truly remarkable is that sorfequiline demonstrated higher bactericidal potency than bedaquiline, a current go-to drug. This not only holds promise for treating drug-sensitive TB but also for tackling the growing threat of bedaquiline-resistant strains.
And this is the part most people miss: sorfequiline belongs to a class of drugs called diarylquinolines, which target the mycobacterial ATP synthase enzyme—essentially starving TB bacteria of energy. Preclinical studies revealed that sorfequiline is approximately ten times more active than bedaquiline, with a favorable safety profile, including a low risk of QT prolongation, a heart-related side effect. Phase 1 clinical trials involving 165 healthy volunteers further confirmed its tolerability, with only mild side effects reported.
The implications are huge. By incorporating sorfequiline into the SPaL regimen, researchers believe they can significantly shorten TB treatment duration, moving closer to the dream of ultra-short, all-oral regimens for both drug-sensitive and drug-resistant TB. This isn’t just about convenience—it’s about saving lives, especially in high-burden settings where long treatment times often lead to poor adherence and treatment failure.
But here’s the controversial part: can we truly shorten TB treatment to as little as one month? The TB Alliance thinks so, and they’re gearing up to advance sorfequiline into Phase 3 trials in 2026, building on their experience with BPaL regimens. They’re exploring innovative delivery methods, including oral therapy and long-acting injectables, to make this a reality. However, researchers caution that optimized dosing and combination strategies will be critical to balancing maximal efficacy with safety.
So, what do you think? Is sorfequiline the game-changer TB treatment has been waiting for, or are we getting ahead of ourselves? Could ultra-short regimens really transform TB care globally, or are there hidden challenges we’re not yet considering? Let’s spark a conversation—share your thoughts in the comments below.
Sorfequiline’s potential to improve efficacy, shorten treatment, and combat resistance makes it a beacon of hope in the fight against TB. As we await Phase 3 trial results, one thing is clear: this drug could redefine the future of TB pharmacotherapy.
Reference:
TB Alliance. Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time. 2025. Available at: https://www.tballiance.org/phase-2-clinical-trial-results-show-potential-to-shorten-tb-treatment-time/. Last accessed: 24 November 2025.
License:
This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/).
